Skip to main content

Table 2 Study design, follow-up, and participant criteria for STTR CJ cohort studies

From: Cohort profile: seek, test, treat and retain United States criminal justice cohort

Studya Study design Follow-up time points Individual inclusion and exclusion criteria
BRIGHT
 BRIGHT 1 Randomized/observational study of on-site rapid HIV testing at probation/parole office vs. off-site referral at a community health center Baseline only Unknown HIV status; on probation or parole in Baltimore, MD or Providence/ Pawtucket, RI and residence in the Baltimore or Providence/Pawtucket area throughout the study period
 BRIGHT 2 RCT of case management (Project Bridge) vs. TAU 3,6,12,15,18 months HIV-infected; on probation or parole in Baltimore, MD and planned residence in greater Baltimore area throughout the study period
CARE+
 RCT RCT of CARE+ Corrections intervention Monthly for 24 months Aged 18+; HIV-infected; released from the correctional facility or half-way house ≤6 months ago and living in Washington, DC metropolitan community (not a restricted setting, e.g. half-way house) or currently detained in jail with anticipated release to community (not a restricted setting); reading at 8th grade level and English-speaking
 HCV RIDOC Cross-sectional study of HCV testing Baseline only Aged 18+; self-reported as HCV negative and documented HCV infection during Department of Corrections time with anticipated release between 3 and 12 weeks from enrollment; English-speaking
 HCV PROB Cross-sectional study of HCV testing Baseline only Aged 18+; self-reported as HCV negative or unknown; on probation or parole; English speaking
IMPACT RCT of IMPACT intervention vs. standard of care 2, 6, 14, and 24 weeks Aged 18+; HIV-infected with HIV RNA < 400 copies/mL receiving ART who were incarcerated in NC or TX and 3 months prior to release and not convicted of sexual assault, death or serious injury; English-speaking
LINK LA RCT of intervention 2, 6, 12 months Male or transgender individuals, aged 18+; HIV infected; incarcerated in a single facility for 5+ days; residing in Los Angeles County, CA upon release; English fluency
NEW HOPE Placebo-controlled RCT of. extended-release naltrexone Monthly for 12 months Aged 18+, HIV-infected, meeting DSM-IV criteria for opioid dependence, within CT corrections system and not pending trial for a felony, within 30 days of being released to greater New Haven, Hartford, Waterbury or Springfield areas or 30 days after release; English- or Spanish-speaking, no liver failure or grade IV hepatitis, no active opioid withdrawal, no receipt of methadone or buprenorphine/naloxone for treatment of opioid dependency, no participation in pharmacotherapy trial in the previous 30 days
STT Observational study of comprehensive Seek Test Treat strategies with medical record linkage 2 years post-release 2 years Aged18+; admitted to a detention facility, expected to be released to Milwaukee County, WI who were willing to be tested for HIV; verbal communication in English
STT ILLINOIS
 OPT OUT Cross-sectional study of opt-out HIV testing Baseline only Aged 18+; detained in the IL corrections system
 CM JAIL Non-randomized study of case-management intervention vs. standard of care 6, 12, 18 months Aged 18+; HIV-infected; detained in IL corrections system (jail); expecting to reside in Chicago after release
 CM PRISON Non-randomized study of case-management intervention vs. standard of care 6, 12, 18 months Aged 18+; HIV-infected; recently released from IL corrections system (prison); enrollment was within 60 days of release
START 1. RCT of CARE-Rapid (computer-assisted program) vs. TAU and 2. quasi-experimental study of manualized intervention vs. TAU, with follow-up at 3 months 3 months Men aged 18+ with either unknown or believed negative HIV status within 90 days of release from NY detention center entering a residential substance abuse treatment program
STRIDE
 STRIDE 1 RCT of buprenorphine vs. placebo Monthly for 12 months Aged 18+; HIV-infected; meeting DSM-IV criteria for opioid dependence; resident of Washington, DC with eligibility for medical entitlements; English- or Spanish-speaking; no current opiate medications for chronic pain conditions or need to be placed on such medications; no current methadone doses over 30 mg/day, no AST and ALT >5× the ULN; no pregnancy or breast-feeding; no liver dysfunction; no suicidal ideation; no participation in pharmacotherapy trial in the previous 30 days
 STRIDE 2 Longitudinal cohort study comparing treatment using opioid substitution therapy to no treatment 3, 6, 9, 12 months Aged 18+; HIV-infected; meeting DSM-IV criteria for opioid dependence; resident of Washington, DC with eligibility for medical entitlements; English-speaking
SUCCESS Non-randomized pilot study of Strengths-Based case management and texting 3, 12 months Aged 18+; HIV-infected; detained or sentenced in jail or detention center and likely to leave within 6 weeks; no recent participation in randomized trial to improve retention in HIV care; English-speaking
UHS II
UHS IIC Cross-sectional study of HIV testing Baseline only Aged 18+; crack cocaine or injection drug use in the past 30 days
UHS IIL Longitudinal cohort study of case management (Project Bridge) vs. usual treatment Quarterly for 24 months Aged 18+; HIV-infected; crack cocaine or injection drug use in the past 30 days
  1. ALT alanine aminotransferase, ART antiretroviral therapy, AST aspartate aminotransferase, CA California, CJ criminal justice, CT Connecticut, DC District of Columbia, DSM-IV Diagnostic and Statistical Manual of Mental Disorders IV, HCV hepatitis C virus, HIV human immunodeficiency virus, IL Illinois, MD Maryland, NC North Carolina, NY New York, RCT randomized controlled trial, RI Rhode Island, RNA ribonucleic acid, TAU treatment as usual, TX Texas, ULN upper limit of normal, WI Wisconsin
  2. aStudy acronyms as in Table 1